Suchergebnisse - (Person:"Liu, Geoffrey")

PubPharm (27)

1

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib : Results of Phase 3 ALTA-3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Yang, J. | Liu, G. | Lu, S. | +11

2

Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer

enthalten in: Clinical colorectal cancer | 2023

von Jiang, D. | Parshad, S. | Zhan, L. | +17

3

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Wakelee, H. | Liberman, M. | Kato, T. | +117

CommentIn: Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. - PMID 38090512

4

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS) : a phase 3, global, multicentre, open-label, randomised controlled study

enthalten in: Lancet (London, England) | 2023

von Lee, S. | Schulz, C. | Prabhash, K. | +23

CommentIn: Lancet. 2023 Aug 5;402(10400):426-427. - PMID 37423230

5

Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer : a mixed methods study

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2023

von Zimmermann, C. | Pope, A. | Hannon, B. | +19

6

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer : updated analysis of data from the phase 3, randomised, open-label CROWN study

enthalten in: The Lancet. Respiratory medicine | 2023

von Solomon, B. | Bauer, T. | Mok, T. | +15

CommentIn: Lancet Respir Med. 2023 Apr;11(4):302-304. - PMID 36535299

7

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis : Implementation on CCTG/AGITG CO.20 trial

enthalten in: Cancer medicine | 2023

von Zhang, J. | Kong, W. | Hu, P. | +10

8

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Mazieres, J. | Iadeluca, L. | Shaw, A. | +11

9

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Solomon, B. | Bauer, T. | Ignatius Ou, S. | +12

CommentIn: J Clin Oncol. 2022 Nov 1;40(31):3564-3568. - PMID 35679525

10

Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens

enthalten in: International journal of cancer | 2022

von Quintanilha, J. | Wang, J. | Sibley, A. | +14